Melanoma News and Research

Latest Melanoma News and Research

American Cancer Society, SU2C partner to fight against cancer

The American Cancer Society, the largest voluntary health organization in the world dedicated to eliminating cancer, and Stand Up To Cancer, the charitable initiative supporting groundbreaking research aimed at getting new treatments to patients in an accelerated timeframe, announced today an historic collaboration in the fight against cancer, which takes more than 585,000 lives in the U.S. each year and nearly 8 million worldwide.

30 Jan 2014

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

A common surgery for non-melanoma skin cancer, known as Mohs surgery typically achieves excellent results but can be a long process, as the surgeon successively removes the area of concern until the surrounding tissue is free of cancer.

29 Jan 2014

CU receives cooperative agreement to develop technological system to determine effects chemical agents

The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.

29 Jan 2014

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Vietnam War veterans with prior exposure to the herbicide Agent Orange may be at higher risk for certain types of skin cancer, suggests a report in the February issue of Plastic and Reconstructive Surgery-, the official medical journal of the American Society of Plastic Surgeons (ASPS).

29 Jan 2014

Response of brain tumors from SRS can indicate necessity of follow-up treatments

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.

28 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

A landmark study across many cancer types reveals that the universe of cancer mutations is much bigger than previously thought. By analyzing the genomes of thousands of patients' tumors, a Broad Institute-led research team has discovered many new cancer genes - expanding the list of known genes tied to these cancers by 25 percent. Moreover, the study shows that many key cancer genes still remain to be discovered.

25 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Selective FAK inhibition within endothelial cells prevents spontaneous tumor metastasis

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, a professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine, has found that a protein involved in promoting tumor growth and survival is also activated in surrounding blood vessels, enabling cancer cells to spread into the bloodstream.

24 Jan 2014

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

Clinical laboratory experts and physicians at Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) achieved 100 percent accuracy in testing for abnormal DNA in cancerous tumor cells with its new gene sequencing equipment and panels.

23 Jan 2014

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body.

22 Jan 2014

EKF Diagnostics announces major breakthrough for PointMan DNA enrichment technology

EKF, announces a major breakthrough for its PointMan DNA enrichment technology for potential use in future cancer testing and treatment.

From EKF Diagnostics 22 Jan 2014

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

15 Jan 2014

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

A team led by investigators from Massachusetts General Hospital, Brigham and Women's Hospital and the Broad Institute has found that a gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.

13 Jan 2014

New study gives hope for novel glioblastoma multiforme treatment

A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme, the most common and most aggressive form of brain cancer, after demonstrating for the first time that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) is a driving force behind the disease's aggressive and invasive nature.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Plasma thermogram can serve as an indicator of cervical cancer

Researchers at the University of Louisville have confirmed that using the heat profile from a person's blood, called a plasma thermogram, can serve as an indicator for the presence or absence of cervical cancer, including the stage of cancer.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Melanoma News and Research

Latest Melanoma News and Research

American Cancer Society, SU2C partner to fight against cancer

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

CU receives cooperative agreement to develop technological system to determine effects chemical agents

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Response of brain tumors from SRS can indicate necessity of follow-up treatments

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Selective FAK inhibition within endothelial cells prevents spontaneous tumor metastasis

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

EKF Diagnostics announces major breakthrough for PointMan DNA enrichment technology

BMH-21 chemical compound has ability to shut down a common cancer process

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

New study gives hope for novel glioblastoma multiforme treatment

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Plasma thermogram can serve as an indicator of cervical cancer

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Melanoma News and Research

Latest Melanoma News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in